Federated Hermes’s Enanta Pharmaceuticals ENTA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-8,534
| Closed | -$49.1K | – | 2097 |
|
|
2024
Q4 | $49.1K | Sell |
8,534
-79,594
| -90% | -$763K | ﹤0.01% | 1670 |
|
|
2024
Q3 | $913K | Sell |
88,128
-42
| -0% | -$549 | ﹤0.01% | 1151 |
|
|
2024
Q2 | $1.14M | Sell |
88,170
-2
| -0% | -$27 | ﹤0.01% | 1063 |
|
|
2024
Q1 | $1.54M | Sell |
88,172
-45,017
| -34% | -$596K | ﹤0.01% | 1010 |
|
|
2023
Q4 | $1.25M | Buy |
+133,189
| New | +$1.24M | ﹤0.01% | 1063 |
|
|
2022
Q1 | – | Sell |
-7
| Closed | -$1K | – | 2228 |
|
|
2021
Q4 | $1K | Hold |
7
| – | – | ﹤0.01% | 2111 |
|
|
2021
Q3 | $1K | Sell |
7
-108
| -94% | -$5.34K | ﹤0.01% | 2134 |
|
|
2021
Q2 | $5K | Sell |
115
-27,376
| -100% | -$1.34M | ﹤0.01% | 2030 |
|
|
2021
Q1 | $1.36M | Sell |
27,491
-38,513
| -58% | -$1.92M | ﹤0.01% | 1254 |
|
|
2020
Q4 | $2.78M | Sell |
66,004
-11,545
| -15% | -$508K | 0.01% | 962 |
|
|
2020
Q3 | $3.55M | Buy |
77,549
+445
| +0.6% | +$21.6K | 0.01% | 811 |
|
|
2020
Q2 | $3.87M | Buy |
77,104
+51,733
| +204% | +$2.68M | 0.01% | 777 |
|
|
2020
Q1 | $1.3M | Buy |
25,371
+25,229
| +17,767% | +$1.34M | ﹤0.01% | 1033 |
|
|
2019
Q4 | $9K | Sell |
142
-8,131
| -98% | -$504K | ﹤0.01% | 1911 |
|
|
2019
Q3 | $497K | Buy |
8,273
+37
| +0.4% | +$2.75K | ﹤0.01% | 1455 |
|
|
2019
Q2 | $695K | Sell |
8,236
-2,610
| -24% | -$235K | ﹤0.01% | 1379 |
|
|
2019
Q1 | $1.04M | Sell |
10,846
-31,761
| -75% | -$2.85M | ﹤0.01% | 1299 |
|
|
2018
Q4 | $3.02M | Sell |
42,607
-13,725
| -24% | -$1.05M | 0.01% | 889 |
|
|
2018
Q3 | $4.81M | Sell |
56,332
-11,220
| -17% | -$1.12M | 0.01% | 819 |
|
|
2018
Q2 | $7.83M | Buy |
67,552
+67,501
| +132,355% | +$6.74M | 0.02% | 550 |
|
|
2018
Q1 | $4K | Buy |
+51
| New | +$3.92K | ﹤0.01% | 1995 |
|
|
2017
Q2 | – | Sell |
-250
| Closed | -$8K | – | 2142 |
|
|
2017
Q1 | $8K | Sell |
250
-210
| -46% | -$6.54K | ﹤0.01% | 1854 |
|
|
2016
Q4 | $15K | Buy |
+460
| New | +$13.2K | ﹤0.01% | 1788 |
|
|
2015
Q2 | – | Sell |
-12,591
| Closed | -$386K | – | 1984 |
|
|
2015
Q1 | $386K | Sell |
12,591
-11,521
| -48% | -$448K | ﹤0.01% | 1427 |
|
|
2014
Q4 | $1.23M | Buy |
24,112
+683
| +3% | +$30.6K | ﹤0.01% | 1113 |
|
|
2014
Q3 | $927K | Buy |
23,429
+23,251
| +13,062% | +$927K | ﹤0.01% | 1215 |
|
|
2014
Q2 | $8K | Buy |
+178
| New | +$6.79K | ﹤0.01% | 1756 |
|
Other funds holding ENTA
FCM
KAM
SCM
Federated Hermes's ENTA Position: Q1 2025 in Review
Federated Hermes sold out of Enanta Pharmaceuticals (ENTA) in Q1 2025, closing a stake of 8,534 shares — an estimated $49.1K sold.
Federated Hermes first reported a position in ENTA in Q2 2014 and held it in 27 quarters. The position peaked at $7.83M in Q2 2018. 109 funds tracked by Wall St. Rank hold ENTA as of Q1 2025.
- Federated Hermes reported no remaining Enanta Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
- Federated Hermes sold 8,534 Enanta Pharmaceuticals shares in Q1 2025, an estimated $49.1K.
- Federated Hermes first reported a position in Enanta Pharmaceuticals in Q2 2014 and held it in 27 quarters.
- Federated Hermes's Enanta Pharmaceuticals position peaked at $7.83M in Q2 2018.
- 109 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q1 2025.
Based on Federated Hermes's 13F filing for Q1 2025, filed 8 May 2025.